Target intelligence / Profile preview

Salmonella Enteritidis O-polysaccharide (SE O-PS)

Target
SE O-PS
Molecular classification
Polysaccharide, Bacterial surface antigen, Lipopolysaccharide component
01

Overview

Salmonella Enteritidis O-polysaccharide is the distal, surface-exposed component of the lipopolysaccharide (LPS) found on the outer membrane of Salmonella enterica serovar Enteritidis. This polysaccharide consists of repeating oligosaccharide units—typically comprising tyvelose, mannose, rhamnose, and galactose—which define the O9 antigenic specificity of the Group D1 Salmonella serogroup (PubMed, PMID: 30213143). Biologically, the O-polysaccharide serves as a protective shield against the host's innate immune system, preventing complement-mediated killing and resisting phagocytosis (NCBI, Bookshelf NBK8435). In clinical medicine, it is a major target for vaccine development, particularly in the form of glycoconjugates where the polysaccharide is linked to a carrier protein to enhance immunogenicity in infants and young children (PubMed, PMID: 28433455). Antibodies directed against this target facilitate the clearance of the bacteria through opsonization and bactericidal activity. Consequently, it is a focal point for both diagnostic serotyping and the development of preventive strategies against salmonellosis and enteric fever (WHO, Salmonella Fact Sheet).

Other names
Salmonella Enteritidis O-antigenSalmonella Group D1 O-antigenLipopolysaccharide O-side chainO-specific polysaccharide
02

Mechanism of action

Induction of protective humoral immunity, specifically the production of opsonophagocytic and bactericidal antibodies that target the bacterial surface for destruction by the immune system.

03

Biological functions

Immune evasionBacterial virulenceStructural integritySerotype specificity
04

Disease associations

InfectionSalmonellosisGastroenteritisBacteremia
05

Safety considerations

Endotoxicity associated with residual Lipid ALow immunogenicity in T-cell independent formSerotype-specific protection limits coverage against other Salmonella strains
06

Interacting drugs

CVD 1931 (Candidate vaccine)

2 more in the full profile.

07

Biomarkers

Anti-O-antigen IgG antibody titerAnti-O-antigen IgM antibody titerSerum bactericidal activity (SBA)

Beyond the preview

Go deeper on Salmonella Enteritidis O-polysaccharide (SE O-PS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salmonella Enteritidis O-polysaccharide (SE O-PS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call